Irish CRO Icon rolls out digital platform developed with Dimension Data

HPE has acquired AI and big data company BlueData for an undisclosed sum (Image PeopleImages / iStockPhoto)
Dublin-based CRO Icon had adopted a new digital platform developed with Dimension Data designed to enhance efficiency and productivity of its clients’ drug and medical device pipelines. (PeopleImages/iStockPhoto)

Dublin-based CRO Icon had adopted a new digital platform developed with Dimension Data designed to enhance efficiency and productivity of its clients’ drug and medical device pipelines.

The platform has been launched throughout the CRO to help support digital trials and patient interaction so that medical professionals can reach those who need it, a Dimension Data spokesperson said in an e-mail.

The platform was designed to aid in reducing complexity and cost for drug and device companies in bring new products to market.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Last year, Icon launched a new, paperless solution for managing the clinical investigator financial disclosure forms mandated by the FDA. Known as Firecrest Financial Disclosure software, it allows sponsors to electronically gather, distribute, track and manage completion of the forms required under the regulatory agency’s rules. The Irish company hopes the system will lower the risks of regulatory noncompliance and reduce administrative costs versus traditional distribution and tracking.

Read more on

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.